Lisdexamfetamine | EPFL Graph Search

Lisdexamfetamine, most commonly sold under the brand name Vyvanse (in the United States) and Elvanse (in most European countries) among others, is a stimulant medication that is used to treat attention deficit hyperactivity disorder (ADHD) in children and adults, and for moderate-to-severe binge eating disorder in adults. Lisdexamfetamine is taken by mouth. Its effects generally begin within two hours and last for up to 14 hours. In the United Kingdom, it is usually less preferred than methylphenidate for the treatment of children. Common side effects of lisdexamfetamine include loss of appetite, anxiety, diarrhea, trouble sleeping, irritability, and nausea. Rare but serious side effects include mania, sudden cardiac death in those with underlying heart problems, and psychosis. It has a high potential for substance abuse per the Drug Enforcement Administration (DEA). Serotonin syndrome may occur if used with certain other medications. Its use during pregnancy may result in harm to the baby and use during breastfeeding is not recommended by the manufacturer. Lisdexamfetamine is an inactive prodrug that works after being converted by the body into dextroamphetamine, a central nervous system (CNS) stimulant. Chemically, lisdexamfetamine is composed of the amino acid L-lysine, attached to dextroamphetamine. Lisdexamfetamine was approved for medical use in the United States in 2007. In 2020, it was the 85th most commonly prescribed medication in the United States, with more than 8 million prescriptions. It is a Class B controlled substance in the United Kingdom and a Schedule II controlled substance in the United States. Lisdexamfetamine is used primarily as a treatment for attention deficit hyperactivity disorder (ADHD) and binge eating disorder; it has similar off-label uses as those of other pharmaceutical amphetamines. Individuals over the age of 65 were not commonly tested in clinical trials of lisdexamfetamine for ADHD. Lisdexamfetamine is available as the dimesylate salt in the form of both oral capsules and chewable tablets.

Molecular analysis and therapeutic applications of human serum albumin-fatty acid interactions

Alessandro Angelini, Alessandro Zorzi, Sara Linciano

Human serum albumin (hSA) is the major carrier protein for fatty acids (FAs) in plasma. Its ability to bind multiple FA moieties with moderate to high affinity has inspired the use of FA conjugation as a safe and natural platform to generate long-lasting t ...

ELSEVIER2022

Sensorimotor conflicts induce somatic passivity and louden quiet voices in healthy listeners

Olaf Blanke, Nathan Quentin Faivre, Giulio Rognini, Oliver Alan Kannape, Pavo Orepic

Sensorimotor conflicts are known to alter the perception of accompanying sensory signals, and deficits in sensory attenuation have been observed in schizophrenia. In the auditory domain, self-generated tones or voices (compared to tones or voices presented ...

2021

Radical-free hyperpolarized MRI using endogenously occurring pyruvate analogues and UV-induced nonpersistent radicals

Rolf Gruetter, Andrea Capozzi, Josefina Adriana Maria Bastiaansen, Hikari Ananda Infinity Yoshihara, Alice Radaelli, Claudia Christina Zanella, Lionel Pierre Arn

It was recently demonstrated that nonpersistent radicals can be generated in frozen solutions of metabolites such as pyruvate by irradiation with UV light, enabling radical-free dissolution dynamic nuclear polarization. Although pyruvate is endogenous, the ...

WILEY2021